Rs 30/Share Dividend: Large Cap Pharma Stock Announces Record Date

Shares of large cap Pharmaceuticals sector stock, Divi's Laboratories Ltd witnessed marginal rise of 0.17% on BSE on July 3 as board of directors of the company declared August 11, 2023 as the record date for Rs 30/- per share dividend of face value Rs 2/- each for the financial year 2022-23. The stock delivered 25% return in last 3-months and declined a little over 1% in last 1-year. Check details below:

Divi's Laboratories Fixes Record Date For Dividend: According to the regulatory filing of the company, "The Company has fixed Friday, August 11, 2023 as the "Record Date" for the purpose of determining the Members eligible to receive dividend for the financial year 2022-23, if approved at the AGM."

Earlier, the company recommended a Dividend of Rs 30/- (i.e. 1,500%) per equity share of face value Rs 2/- each for the financial year 2022-23, subject to approval of the members at the ensuing 33rd Annual General Meeting (AGM). The dividend shall be credited / warrants thereof dispatched within specified timelines from the conclusion of the AGM. The AGM date and record date for the purpose of the payment of dividend will be announced in due course.

Divi's Laboratories Stock Outlook & Return: Last trading price of Divi's Laboratories share is Rs 3589.05 per share. Its 52-week high price is Rs 3976.70 per share and 52-week low price is Rs 2730.00 per share, respectively. Its market capitalisation is Rs 95,278.00 crore. Investors received 63% return on the shares of Divi's Laboratories in last 3-years. Divi's Laboratories stock declined 21% in last 2-years.

Divi's Laboratories Financial Performance: The company for the quarter ended March 31, 2023 announced its consolidated total income at Rs 2016.92 crore, up 10.70% from previous quarter total income of Rs 1821.93 crore. It announced its net profit after tax at Rs 320.97 crore in the latest quarter.

Divi's Laboratories About: Established in the year 1990, Divi's is a leading manufacturer of Active Pharmaceutical Ingredients offering high quality products to over 95 countries. Divi's manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products, according to its official website.

Disclaimer: The stock just highlights the dividend and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for ay losses. Please consult a professional advisor.